Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib
in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in
subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for
curative intent treatment.